Primitive AML progenitors from most CD34+ patients lack CD33 expression but progenitors from many CD34− AML patients express CD33

These data suggest that most leukemic progenitors of CD34+ patients do not express CD33. In contrast, CD34− AML primitive leukemic progenitors may be CD33+. CD34− AML patients could potentially benefit most from CD33-targeted therapies or purging.